Skip to main content
Premium Trial:

Request an Annual Quote

Private Equity Firm to Acquire SeraCare for $82M

NEW YORK (GenomeWeb News) – SeraCare Life Sciences has signed a definitive agreement to be acquired by private equity firm Linden Capital Partners for $4 per share, or around $82 million.

The purchase price represents a 25 percent premium to the 30-day volume-weighted average stock price of SeraCare. The Milford, Mass.-based firm, which makes life sciences tools including molecular biomarkers and controls, would become a private company, wholly owned by Linden.

SeraCare said that its board of directors has unanimously approved the deal. The firm also intends to hold a special meeting of shareholders for approval of the transaction, and if it gains that approval it expects to close the deal in the second quarter.

"Linden is a natural strategic fit for SeraCare with a proven record of operating successful companies in the healthcare and life sciences sectors," Greg Gould, interim president, CEO, and CFO of SeraCare, said in a statement. "Linden's acquisition of SeraCare recognizes our accomplishments and translates them into significant value for our shareholders."

In early Monday trade on the Nasdaq, shares of SeraCare climbed 10 percent to $3.93. Its 52-week high is $4.48.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.